TY - JOUR
T1 - Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems
AU - Subhash, Nayana E.
AU - Prabhu, Meghana
AU - Hazarika, Manali
AU - S, Shailaja
AU - Bhandary, Sulatha V.
AU - Guru, Bharath Raja
N1 - Publisher Copyright:
© The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2025
Y1 - 2025
N2 - The eye is an essential sense organ and drug delivery to the eye is a challenging task due to protective barriers that hinder drug penetration. Over 90 percent of treatments for eye diseases are topical, but frequent administration over extended periods can lead to toxicity and compliance issues. Over the years, extensive research has been aimed at developing drug delivery systems that enhance drug bioavailability at the target site while minimizing side effects. Innovative drug carrier systems have been researched and developed to extend retention time, decrease administration frequency, improve therapeutic efficacy, and ensure biocompatibility. In this article, we delve into the various ocular barriers affecting drug delivery and provide an overview of the utilization of biomaterials and nanotechnology in ocular drug delivery. We explore its applications in the treatment and management of various diseases affecting the anterior segment of the eye.
AB - The eye is an essential sense organ and drug delivery to the eye is a challenging task due to protective barriers that hinder drug penetration. Over 90 percent of treatments for eye diseases are topical, but frequent administration over extended periods can lead to toxicity and compliance issues. Over the years, extensive research has been aimed at developing drug delivery systems that enhance drug bioavailability at the target site while minimizing side effects. Innovative drug carrier systems have been researched and developed to extend retention time, decrease administration frequency, improve therapeutic efficacy, and ensure biocompatibility. In this article, we delve into the various ocular barriers affecting drug delivery and provide an overview of the utilization of biomaterials and nanotechnology in ocular drug delivery. We explore its applications in the treatment and management of various diseases affecting the anterior segment of the eye.
UR - https://www.scopus.com/pages/publications/105014182507
UR - https://www.scopus.com/inward/citedby.url?scp=105014182507&partnerID=8YFLogxK
U2 - 10.1177/08853282251369229
DO - 10.1177/08853282251369229
M3 - Review article
C2 - 40811684
AN - SCOPUS:105014182507
SN - 0885-3282
JO - Journal of Biomaterials Applications
JF - Journal of Biomaterials Applications
M1 - 08853282251369229
ER -